Coloplast develops products for people with intimate health care needs. Animal testing is sometimes required in order to ensure the safety of our products. Further, some authorities require documentation obtained through animal testing. For these reasons, Coloplast cannot completely avoid animal testing in the development and approval of our products.

Coloplast acknowledges the concerns that animal testing raise. We adhere to the “three R’s”:

- **Replacement** – using non-animal testing methods (e.g. testing with cell cultures or through computer modelling)
- **Refinement** – using test methods which minimise the potential distress to animals
- **Reduction** – using fewer animals to obtain the same level of information

We communicate openly about the actual numbers of animal tests in our annual Corporate Responsibility report. The numbers are relatively limited compared to other medical companies in general.

We constantly challenge the need for animal testing and implement the “three R” principles in our product development and maintenance whenever possible. Thus we replace animal testing by:

- using existing data for applied materials
- using chemical characterisation (chemical and/or physical analyses) of materials and devices
- testing with cell cultures

When animal testing is required, we refine and reduce the testing by:

- testing devices solely in their most mature development stage whenever possible
- using test methods that cause the least distress to animals

Further, we only use suppliers who comply with legislation and international standards relating to animal welfare. We regularly monitor our suppliers to ensure compliance.

The overall responsibility for this policy lies with Coloplast’s CFO, a member of Executive Management. The operational responsibility lies in Corp. Quality & Environment with the Director for Environment, Health & Safety Development.

September 2011

Lene Skole  
Executive Vice President